BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16029222)

  • 1. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
    Mc Donnell CG; Shorten G; Van Pelt FN
    Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
    Toda T; Eliasson E; Ask B; Inotsume N; Rane A
    Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
    Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
    J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.
    Fischer V; Johanson L; Heitz F; Tullman R; Graham E; Baldeck JP; Robinson WT
    Drug Metab Dispos; 1999 Mar; 27(3):410-6. PubMed ID: 10064574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
    Dansette PM; Jaoen M; Pons C
    Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
    Tornio A; Pasanen MK; Laitila J; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2005 Aug; 97(2):104-8. PubMed ID: 15998357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
    Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
    Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.
    Liantonio A; Giannuzzi V; Cippone V; Camerino GM; Pierno S; Camerino DC
    J Pharmacol Exp Ther; 2007 May; 321(2):626-34. PubMed ID: 17293561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of statins on fibroblasts from human nasal polyps and turbinates.
    Folli C; Descalzi D; Bertolini S; Riccio AM; Scordamaglia F; Gamalero C; Barbieri M; Passalacqua G; Canonica GW
    Eur Ann Allergy Clin Immunol; 2008 Nov; 40(3):84-9. PubMed ID: 19334372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
    Turner NA; Midgley L; O'Regan DJ; Porter KE
    J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
    Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
    Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam.
    Mc Donnell CG; Harte S; O'Driscoll J; O'Loughlin C; Van Pelt FN; Shorten GD
    Anaesthesia; 2003 Sep; 58(9):899-904. PubMed ID: 12911366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin.
    Transon C; Leemann T; Vogt N; Dayer P
    Clin Pharmacol Ther; 1995 Oct; 58(4):412-7. PubMed ID: 7586933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
    Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
    Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.
    Pierno S; Camerino GM; Cippone V; Rolland JF; Desaphy JF; De Luca A; Liantonio A; Bianco G; Kunic JD; George AL; Conte Camerino D
    Br J Pharmacol; 2009 Apr; 156(8):1206-15. PubMed ID: 19220292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.
    Transon C; Leemann T; Dayer P
    Eur J Clin Pharmacol; 1996; 50(3):209-15. PubMed ID: 8737761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
    Lopez S; Peiretti F; Bonardo B; Juhan-Vague I; Nalbone G
    Atherosclerosis; 2000 Oct; 152(2):359-66. PubMed ID: 10998463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research on the effect of statins on insulin secretion from pancreatic islet in rats and its mechanisms].
    Chang BC; Zheng MY; Shan CY; Yang JH; Wang Y; Ren HZ; Chen LM; Fang PH
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):393-6. PubMed ID: 21624221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
    Bhoopathy S; Xin B; Unger SE; Karnes HT
    J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.